Published in PLoS One on May 23, 2011
Quantification of the Blood Platelet Reactivity in the ADP-Induced Model of Non-Lethal Pulmonary Thromboembolism in Mice with the Use of Laser Doppler Flowmetry. PLoS One (2016) 1.38
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35
Qishenyiqi protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-κB signaling pathway. PLoS One (2014) 0.91
Chebulagic acid inhibits the LPS-induced expression of TNF-α and IL-1β in endothelial cells by suppressing MAPK activation. Exp Ther Med (2015) 0.81
Aspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test. FASEB J (2013) 0.78
Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. Blood (2015) 0.78
Impact of wines and wine constituents on cyclooxygenase-1, cyclooxygenase-2, and 5-lipoxygenase catalytic activity. Mediators Inflamm (2014) 0.76
Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulation. Intensive Care Med Exp (2015) 0.75
Licochalcones extracted from Glycyrrhiza inflata inhibit platelet aggregation accompanied by inhibition of COX-1 activity. PLoS One (2017) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Platelet activation and atherothrombosis. N Engl J Med (2007) 6.18
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16
Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation (2007) 3.27
The growing complexity of platelet aggregation. Blood (2007) 2.81
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J (2004) 2.75
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10
Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature (1978) 2.10
COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov (2006) 1.62
Prostacyclin is a circulating hormone. Nature (1978) 1.60
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest (2001) 1.45
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.38
Role of platelets in atherothrombosis. Am J Cardiol (2009) 1.36
Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol (1984) 1.29
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet (2008) 1.29
The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol (2000) 1.26
Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci (2007) 1.24
Cyclooxygenase in normal human tissues--is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med (2008) 1.18
Reference curves for aggregation and ATP secretion to aid diagnose of platelet-based bleeding disorders: effect of inhibition of ADP and thromboxane A(2) pathways. Platelets (2007) 1.17
Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins (1980) 1.15
Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension (2007) 1.09
The roles of alpha IIb beta 3-mediated outside-in signal transduction, thromboxane A2, and adenosine diphosphate in collagen-induced platelet aggregation. Blood (2002) 1.07
Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost (2008) 1.05
Real-time measurement of non-lethal platelet thromboembolic responses in the anaesthetized mouse. Thromb Haemost (2008) 1.03
Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. Mol Interv (2009) 1.00
Role of shear stress in endothelial cell morphology and expression of cyclooxygenase isoforms. Arterioscler Thromb Vasc Biol (2010) 1.00
Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol (1999) 0.99
N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem (2000) 0.95
Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. Biochem Pharmacol (1984) 0.94
Comparison of the effect of intravenous ketoprofen, ketorolac and diclofenac on platelet function in volunteers. Acta Anaesthesiol Scand (1997) 0.90
Functional regulation of vascular and platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase. Thromb Haemost (2010) 0.87
Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol (2001) 0.81
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
Animal research: reporting in vivo experiments: the ARRIVE guidelines. J Gene Med (2010) 2.86
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J (2004) 2.75
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacother (2010) 2.27
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
Circulating microRNAs as novel biomarkers for platelet activation. Circ Res (2013) 2.22
Animal research: reporting in vivo experiments--the ARRIVE guidelines. J Cereb Blood Flow Metab (2011) 1.80
Pharmacology and therapeutic potential of interferons. Pharmacol Ther (2012) 1.76
Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol (2006) 1.74
COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov (2006) 1.62
Intestinal injury and endotoxemia in children undergoing surgery for congenital heart disease. Am J Respir Crit Care Med (2011) 1.57
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart (2010) 1.57
Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. Cardiovasc Res (2011) 1.53
Endothelial nitric oxide synthase activity is inhibited by the plasma membrane calcium ATPase in human endothelial cells. Cardiovasc Res (2010) 1.51
Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A (2004) 1.48
Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci U S A (2002) 1.44
The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J Biol Chem (2006) 1.41
Plasma membrane Ca2+ ATPase 4 is required for sperm motility and male fertility. J Biol Chem (2004) 1.37
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35
The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res (2006) 1.31
Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet (2006) 1.30
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet (2008) 1.29
Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b. Circulation (2007) 1.27
Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol (2007) 1.22
Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. FASEB J (2005) 1.18
Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J (2005) 1.18
Role of TLR2, TLR4, and MyD88 in murine ozone-induced airway hyperresponsiveness and neutrophilia. J Appl Physiol (1985) (2007) 1.18
The sarcolemmal calcium pump inhibits the calcineurin/nuclear factor of activated T-cell pathway via interaction with the calcineurin A catalytic subunit. J Biol Chem (2005) 1.14
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol (2009) 1.13
Cigarette smoke induces IL-8, but inhibits eotaxin and RANTES release from airway smooth muscle. Respir Res (2005) 1.12
Novel functional interaction between the plasma membrane Ca2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). J Biol Chem (2004) 1.12
Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappaB binding and histone acetylation at specific kappaB sites. J Biol Chem (2009) 1.12
Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: implications for steroid resistance. Mol Pharmacol (2005) 1.11
Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J Pharmacol Exp Ther (2002) 1.11
Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem (2005) 1.10
Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol (2009) 1.10
Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. Am J Respir Crit Care Med (2010) 1.10
Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am J Respir Crit Care Med (2007) 1.09
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol (2005) 1.08
Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res (2013) 1.08
Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood (2007) 1.05
Differential effects of Gram-positive versus Gram-negative bacteria on NOSII and TNFalpha in macrophages: role of TLRs in synergy between the two. Br J Pharmacol (2006) 1.04
The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo. PLoS One (2009) 1.04
Real-time measurement of non-lethal platelet thromboembolic responses in the anaesthetized mouse. Thromb Haemost (2008) 1.03
Innate immunity in human embryonic stem cells: comparison with adult human endothelial cells. PLoS One (2010) 1.02
Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J (2006) 1.02
Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci U S A (2010) 1.02
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. Am J Physiol Heart Circ Physiol (2007) 1.01
Role of shear stress in endothelial cell morphology and expression of cyclooxygenase isoforms. Arterioscler Thromb Vasc Biol (2010) 1.00
Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc Natl Acad Sci U S A (2005) 0.99
Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol (2009) 0.99
Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One (2011) 0.99
PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J (2003) 0.98
Scanning ion conductance microscopy: a convergent high-resolution technology for multi-parametric analysis of living cardiovascular cells. J R Soc Interface (2011) 0.98
Toll-like receptor 2 is essential for the sensing of oxidants during inflammation. Am J Respir Crit Care Med (2008) 0.97
Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol (2002) 0.97
Cyclo-oxygenase-2 inhibitors and cardiovascular events. Lancet (2002) 0.96
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Vet Clin Pathol (2012) 0.95
Not so EEZE: the 'EDHF' antagonist 14, 15 epoxyeicosa-5(Z)-enoic acid has vasodilator properties in mesenteric arteries. Eur J Pharmacol (2004) 0.95
Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost (2009) 0.94
Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol Pharmacol (2003) 0.93
Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res (2002) 0.93
Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain. J Biol Chem (2011) 0.93
Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-α. Gut (2012) 0.93
Inflammatory transcriptome profiling of human monocytes exposed acutely to cigarette smoke. PLoS One (2012) 0.92
Proteome-wide analysis and CXCL4 in systemic sclerosis. N Engl J Med (2014) 0.92
Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood (2007) 0.92
Crucial role of TNF receptors 1 and 2 in the control of polymicrobial sepsis. J Immunol (2009) 0.91
Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ (2012) 0.90
The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells. Biochem Biophys Res Commun (2006) 0.90
Interleukin-1beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo. Am J Physiol Renal Physiol (2008) 0.89
COX-2 in cardiovascular disease. Arterioscler Thromb Vasc Biol (2006) 0.89
Novel role for P2X receptor activation in endothelium-dependent vasodilation. Br J Pharmacol (2004) 0.88
LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One (2013) 0.88
The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One (2010) 0.87
Heme oxygenase is expressed in human pulmonary artery smooth muscle where carbon monoxide has an anti-proliferative role. Eur J Pharmacol (2003) 0.87
Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sci (2002) 0.87